EDNRB

Endothelin receptor type B · P24530 · EDNRB on Sugi Atlas →

36,595 patent compounds predicted against EDNRB, 22,534 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Darusentan (SCHEMBL795084)	1.00	20/20
A-192621 (SCHEMBL1030269)	1.00	20/20
Darusentan (SCHEMBL1068546)	1.00	20/20
SCHEMBL1068402	0.81	20/20
SCHEMBL999054	0.77	20/20
SCHEMBL1067551	0.73	20/20
SCHEMBL1067548	0.70	20/20
SCHEMBL1067657	0.69	20/20
SCHEMBL1065348	0.62	20/20
SCHEMBL1003217	0.60	20/20
SCHEMBL1068290	0.55	20/20
SCHEMBL1069539	0.55	20/20
Tezosentan (SCHEMBL4525)	1.00	19/20
SCHEMBL803855	1.00	19/20
SCHEMBL1000608	1.00	19/20
Enrasentan (SCHEMBL1031130)	1.00	19/20
Macitentan (SCHEMBL1445625)	1.00	19/20
Enrasentan (SCHEMBL1649828)	1.00	19/20
Tezosentan (SCHEMBL387773)	0.99	19/20
SCHEMBL1000701	0.83	19/20

Clinical trials — most relevant to EDNRB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Estradiol on Endothelial Function in Peri-Menopausal Women	PHASE4	ACTIVE_NOT_RECRUITING
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)	PHASE4	UNKNOWN
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.	PHASE3	COMPLETED
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans	PHASE3	COMPLETED
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma	PHASE2	UNKNOWN
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis	PHASE2	COMPLETED
Endothelin-1 Receptor Blockade in Resistant Hypertension	PHASE2	RECRUITING
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)	PHASE2	ACTIVE_NOT_RECRUITING
Endothelin-Receptor Blockade in Coronary Heart Disease	PHASE1	COMPLETED
Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension	PHASE1	COMPLETED
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects	PHASE1	COMPLETED
Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)	EARLY_PHASE1	COMPLETED
Adiposity and Endothelin Receptor Function	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH	nan	COMPLETED
Pharmacogenomics in Pulmonary Arterial Hypertension	nan	WITHDRAWN
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension	nan	RECRUITING
Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension	nan	COMPLETED
Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002	nan	UNKNOWN
Role of Endothelin-1 in Flow-mediated Dilatation	nan	COMPLETED
Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease	nan	UNKNOWN
Menopause Effects on Vascular Function	nan	COMPLETED
The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries	nan	COMPLETED
Gap Junction Potentiation of Endothelial Function With Rotigaptide	nan	COMPLETED
Endothelial Effects of VEGF Inhibition In Vivo in Man	nan	COMPLETED
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome	nan	UNKNOWN
Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension	nan	COMPLETED
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EDNRB binder may also engage these)

Protein	Name	Similarity
P56497	—	1.000	P56497 →
O62709	—	1.000	O62709 →
P48302	—	1.000	P48302 →
Q9N0W7	—	1.000	Q9N0W7 →
P35463	—	1.000	P35463 →
P21451	—	0.999	P21451 →
P28088	—	0.994	P28088 →
Q61614	—	0.983	Q61614 →
Q5KSU9	—	0.980	Q5KSU9 →
P26684	—	0.980	P26684 →
P21450	—	0.978	P21450 →
EDNRA	Endothelin-1 receptor	0.976	landscape →
Q95L55	—	0.976	Q95L55 →
Q29010	—	0.970	Q29010 →
P24053	—	0.956	P24053 →
B2ZI34	—	0.953	B2ZI34 →
O54799	—	0.951	O54799 →
NMBR	Neuromedin-B receptor	0.950	landscape →
P42866	—	0.944	P42866 →
GRPR	Gastrin-releasing peptide receptor	0.942	landscape →
Q5IS39	—	0.942	Q5IS39 →
P21729	—	0.941	P21729 →
P79350	—	0.940	P79350 →
Q95M54	—	0.939	Q95M54 →
OPRM1	Mu-type opioid receptor	0.938	landscape →
P52500	—	0.938	P52500 →
Q95247	—	0.937	Q95247 →
Q5IS84	—	0.936	Q5IS84 →
P33534	—	0.936	P33534 →
P41144	—	0.935	P41144 →